Decreased SIRT1 expression in the peripheral blood of patients with Graves' disease

J Endocrinol. 2020 Aug;246(2):161-173. doi: 10.1530/JOE-19-0501.

Abstract

SIRT1, a class III histone/protein deacetylase (HDAC), has been associated with autoimmune diseases. There is a paucity of data about the role of SIRT1 in Graves' disease. The aim of this study was to investigate the role of SIRT1 in the pathogenesis of GD. Here, we showed that SIRT1 expression and activity were significantly decreased in GD patients compared with healthy controls. The NF-κB pathway was activated in the peripheral blood of GD patients. The reduced SIRT1 levels correlated strongly with clinical parameters. In euthyroid patients, SIRT1 expression was markedly upregulated and NF-κB downstream target gene expression was significantly reduced. SIRT1 inhibited the NF-κB pathway activity by deacetylating P65. These results demonstrate that reduced SIRT1 expression and activity contribute to the activation of the NF-κB pathway and may be involved in the pathogenesis of GD.

Keywords: Graves’ disease; NF-κB; SIRT1; thyroid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Graves Disease / genetics
  • Graves Disease / metabolism*
  • Humans
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Signal Transduction / genetics
  • Signal Transduction / physiology
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism*
  • Thyroid Gland / metabolism*

Substances

  • NF-kappa B
  • Sirtuin 1